Current approaches to antithrombotic therapy in patients with cardioembolic stroke
https://doi.org/10.14412/2074-2711-2013-2356
Abstract
The rate of cardiogenic embolism among all ischemic strokes is as high as 38%. Cardioembolic strokes are characterized by the higher magnitude of neurological deficit, the high risk of recurrent acute stroke, and a lethal outcome. This review deals with the etiopathogenesis of thrombus formation in the heart chambers, with current criteria for the verification of cardioembolic strokes, with the results of trials of new oral anticoagulants, and latest guidelines for antithrombotic therapy to prevent stroke. Special focus is given to secondary stroke prevention in patients with nonvalvular atrial fibrillation since it is atrial fibrillation that is the most common cause of cardioembolic stroke.
About the Authors
Oleg Ivanovich Vinogradov
N.I. Pirogov National Medical Surgical Center, Moscow
Russian Federation
Russian Federation
A N Kuznetsov
N.I. Pirogov National Medical Surgical Center, Moscow
Russian Federation
Russian Federation
N V Rybalko
N.I. Pirogov National Medical Surgical Center, Moscow
Russian Federation
Russian Federation
References
1. <div><p>Adams HP Jr, Bendixen BH, Kappele LJ et al. Classification of sybtype of acute stroke: Definituin for use in a multicentre clinical trial, TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke.1993;24(1):35–41.</p><p>Кузнецов АН, Виноградов ОИ, Кучеренко СС. Ишемический инсульт. Диагностика. Лечение. Профилактика: карманный справочник. Mосква: РАЕН; 2012. [Kuznetsov AN, Vinogradov OI, Kucherenko SS. Ishemicheskiy insul't. Diagnostika. Lechenie. Profilaktika: karmannyy spravochnik. Moscow: RAEN; 2012.]</p><p>Инсульт. Принципы диагностики, лечения и профилактики. Краткое руководство для врачей. Под редакцией Верещагина НВ, Пирадова МА, Суслиной ЗА. Москва: Интермедика; 2002. 208 с. [Insul't. Printsipy diagnostiki, lecheniya i profilaktiki. Kratkoe rukovodstvo dlya vrachey. Pod redaktsiey Vereshchagina NV, Piradova MA, Suslinoy ZA. Mosсow: Intermedika; 2002. 208 р.]</p><p>Шевченко ЮЛ, Одинак АН, Кузнецов АН, Ерофеев АА. Кардиогенный и ангиогенный церебральный эмболический инсульт. Москва: ГЭОТАР-Медиа; 2006. 272 с. [Shevchenko YuL, Odinak AN, Kuznetsov AN, Erofeev AA. Kardiogennyy i angiogennyy tserebral'nyy embolicheskiy insul't. Moscow: GEOTAR-Media; 2006. 272 p.]</p><p>Шевченко ЮЛ, Михайленко АА, Кузнецов АН, Ерофеев АА. Кардиохирургическая агрессия и головной мозг. Санкт-Петербург: Наука; 1997. 152 c. [Shevchenko YuL, Mikhaylenko AA, Kuznetsov AN, Erofeev AA. Kardiokhirurgicheskaya agressiya i golovnoy mozg. St.-Petersburg: Nauka; 1997. 152 p.]</p><p>Практическая кардионеврология. Под редакцией Суслиной ЗА, Фонякина АВ. Москва: ИМА-ПРЕСС; 2010. 304 с. [Prakticheskaya kardionevrologiya. Pod redaktsiey Suslinoy ZA, Fonyakina AV. Moscow: IMA-PRESS; 2010. 304 p.]</p><p>Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the stroke prevention in atrial fibrillation study. J Stroke Cerebrovasc Dis. 1995;5(3):147–57.</p><p>Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28(10): 973–7. DOI: 10.1212%2FWNL.28.10.973.</p><p>Caplan LR. Brain embolism revisited. Neurology. 1993;43:1281–7. DOI: 10.1212%2FWNL.43.7.1281.</p><p>Наnna JP, Furlan AJ. Cardiac disease and embolic sources. Brain ischemia: Basic concepts and clinical relevalence. Caplan – Lond LD, editor. Springer-Verlag. 1995;299–315.</p><p>Arboixa A, Alioc J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev.2010;6(3):150–61. DOI: 10.2174%2F157340310791658730.</p><p>Johnson RC, Crissman RS, DiDio LJA. Endocardial alterationin myocardial infarction. Lab Invest. 1979;40:183–93.</p><p>Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: Analysis of 152 necropsy patients. Am J Cardiol. 1987;60(16):1340–55. DOI: 10.1016%2F0002-9149%2887%2990618-7.</p><p>Нochman JS, Platia EB, Bulkley BH. Endocardial abnormalities in left ventricular aneurysm. A clinicopathologic study. Ann Intern Med. 1984;100(1):29–35.</p><p>Francis CW, Markham RE, Barlow GH et al. Thrombin activity of fibrin thrombi and soluble plasmic derivates. J Lab Clin Med. 1983;102(2):220–30.</p><p>Lassila R, Badimon JJ, Vallabhajasula S, Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenosis on thrombus growth. Arteriosclerosis. 1990;10(2):306–15. DOI: 10.1161%2F01.ATV.10.2.306.</p><p>Visser CA, Kan G, Meltzer RS et al. Long-term follow-up of left ventricular thrombus after acute myocardial infarction. A two-dimensional echocardiographic study in 96 patients. Chest. 1984;86(4):532–6. DOI: 10.1378%2Fchest.86.4.532.</p><p>Lapeyre AC, Steele PM, Kazmier FJ at al. Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation. J Am Coll Cardiol. 1985;6(3):534–8. DOI: 10.1016%2FS0735-1097%2885%2980109-1.</p><p>Cabin HS, Roberts WC. Left ventricular aneyrism, intra-aneurismal thrombus and systemic embolus in coronary heart disease. Chest.1980;77(5):586–90.</p><p>Dauzat M, Deklunder G, Aldis A et al. Gas bubble emboli detected by transcranial Doppler sonography in patients with prosthetic heart valves: a preliminary report. J Ultrasound Med. 1994:13(2):129–35.</p><p>Georgiadis D. Microembolism in prosthetic valve patients. Stroke. 1998;29:2237.</p><p>Abdoh N, Zettervall O, Carlson J et al. Is occult atrial disorder a frequent cause of non-Hemorragic stroke? Long-term ECG in 86 patients. Stroke. 1982;13(6):832–7.</p><p>Delcker A, Diener HC. Neurologische Diagnostik und therapeutische Massnahmen bei zerebralen Embolien. Herz. 1991;16(6):434–43.</p><p>Cujec B, Polasek P, Voll C, Shuaib A. Transesophageal echocardiography in the detection of potential cardiac source of embolism in stroke patients. Stroke. 1991;22(6):727–33. DOI: 10.1161%2F01.STR.22.6.727.</p><p>Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med. 1994;154(13):1443–8. DOI: 10.1001%2Farchinte.1994.00420130030006.</p><p>Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110(9):e82–292.</p><p>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–57.</p><p>Font, Krupinski J, Arboix A. Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat. 2011;2011:607852. DOI: 10.4061/2011/607852. Epub 2011 Jun 22.</p><p>Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18): 2370–5.</p><p>Van Walraven C, Hart RC, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–8. DOI: 10.1001%2Fjama.288.19.2441.</p><p>Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):429S-456S. DOI: 10.1378%2Fchest.126.3_suppl.429S.</p><p>Домашенко МА, Макcимова МЮ, Коробкова ДЗ, Гафарова МЭ. Опыт применения дабигатрана в первичной и вторичной профилактики кардио-эмболического инсульта. Неврология, нейропсихиатрия, психосоматика. 2013;2:69–77. [Domashenko MA, Makcimova MYu, Korobkova DZ, Gafarova ME. Opyt primeneniya dabigatrana v pervichnoy i vtorichnoy profilaktiki kardio-embolicheskogo insul'ta. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2013;2:69–77.]</p><p>Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342(8882):1255–62.</p><p>Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1863–2372. DOI: 10.1056/NEJMc1007378.</p><p>Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation. 2012;125(5):669–76. DOI: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.</p><p>Meissner I, Khandheria BK, Heit JA et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47(2):440–5. Epub 2005 Dec 6.</p><p>Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001 Nov 1;345(18):1318-30. DOI: 10.1056%2FNEJMra010082.</p><p>Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous tresient ischemic attack or stroke: a subgroup analysis of RE-LY trial. Lancet Neurol. 2010;9: 1157–63. DOI: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6.</p><p>Van de Werf F, Brueckmann M, Connolly SJ et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6):931–7.e1. DOI: 10.1016/j.ahj.2012.03.011.</p><p>Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</p><p>Furie KL, Goldstein LB, Albers GW et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 Dec;43(12):3442–53. DOI: 10.1161/STR.0b013e318266722a. Epub 2012 Aug 2.</p><p>Visser CA, Kan G, Meltzer RS et al. Embolic potential of left ventricular thrombus after myocardial infarction: A two-dimentional echocardiographic study of 119 patients. J Am Coll Cardiol. 1985;5(6):1276–80.</p><p>Loh E, Sutton MC, Wun CC et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997 Jan 23;336(4):251–7. DOI: 10.1056%2FNEJM199701233360403.</p><p>Natarajan D, Hotchandani RK, Nigam PD. Reduced incidence of left ventricular thrombi with intravenous streptokinase in acute anterior myocardial infarction: prospective evaluation by cross-sectional echocardiography. Int J Cardiol. 1988;20(2):201–7. DOI: 10.1016%2F0167-5273%2888%2990264-1.</p><p>Sherman DG, Dyken ML, Fisher M et al. Cerebral embolism. Chest. 1986;89(suppl 2):82S–98S.</p><p>Held AC, Gore JM, Paraskos J et al. Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction. Am J Cardiol. 1988;62(4):310–1.</p><p>Azar AJ, Koudstaal PJ, Wintzen AR et al. Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. Ann Neurol. 1996;39(3):301–7. DOI: 10.1002%2Fana.410390306.</p><p>Van Es RF, Jonker JJ, Verheugt FW et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109–13. DOI: 10.1016%2FS0140-6736%2802%2909409-6.</p><p>Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79(7):909–13. DOI: 10.1016%2FS0002-9149%2897%2900013-1.</p><p>Salem DN, Stein PD, Al-Ahmad A et al. Antithrombotic therapy in valvular heart disease–native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):457S-482S. DOI: 10.1378%2Fchest.126.3_suppl.457S.</p><p>American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006 Aug 1;114(5):e84–231.</p><p>Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med. 1996 Aug 8;335(6):407–16. DOI: 10.1056%2FNEJM199608083350607.</p><p>Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(2):577–617. DOI: 10.1161%2F01.STR.0000199147.30016.74.</p><p>Heiro M, Nikoskelainen J, Engblom E et al. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000;160(18):2781–7. DOI: 10.1001%2Farchinte.160.18.2781.</p></div><br />
Review
For citations:
Vinogradov OI, Kuznetsov AN, Rybalko NV. Current approaches to antithrombotic therapy in patients with cardioembolic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2S):28-39. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2356
Views:
1065
Email this article 